Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

285,40 +2,00 (+0,71%) Alla chiusura: 12:59PM CEST

Swedish Orphan Biovitrum AB (publ)

Tomtebodavägen 23A
Solna 112 76
Sweden
46 86 97 20 00
https://www.sobi.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 1.752

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Guido Oelkers	CEO & President	25,82M	N/D	1965
Mr. Henrik Stenqvist	Chief Financial Officer	N/D	N/D	1967
Mr. Torbjörn Hallberg	General Counsel & Head of Legal Affairs	N/D	N/D	1969
Mr. Daniel Rankin	Head of Strategy & Corporate Development	N/D	N/D	1980
Ms. Lena Bjurner	Head of Human Resources	N/D	N/D	1968
Mr. Armin Reininger M.D., Ph.D.	Senior Scientific & Medical Advisor	N/D	N/D	1957
Mr. Norbert Oppitz	Head of International	N/D	N/D	1967
Mr. Sofiane Fahmy	Head of Europe	N/D	N/D	1972
Mr. Duane H. Barnes	Head of North America	N/D	N/D	1960
Mr. Mahmood Ladha	Head of Strategic Transformation Operations	N/D	N/D	1964

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Swedish Orphan Biovitrum AB (publ) al 29 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 1; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.